2025 Q4 -tulosraportti
Vain PDF
91 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·33 min sitten · MuokattuArticle with Erik Wiklund from today https://themedicinemaker.com/issues/2026/articles/july/surviving-cgts-funding-winter/Article: Investors are now only funding the strongest CGT companies. * Circio: Has raised approx. NOK 620 million (USD 65 mill.) in 2026, which shows that the company has managed to attract significant capital in a demanding market. Article: Long cash reserves ("runway") are a major competitive advantage. * Circio: States that the financing provides operations until the end of 2030, which reduces the risk of new share issues in the short term. Article: Platform technologies are valued higher than single products. * Circio: Focuses on circVec, a circular RNA platform that can be used in several types of gene and cell therapies, not just one drug. Article: Partnerships with Big Pharma are becoming increasingly important. * Circio: Has already announced a collaboration with a top-5 global pharmaceutical company, which aligns well with this trend. Article: Companies must show a clear path towards clinical trials. * Circio: Has stated that the capital will be used to take a leading gene therapy program to IND and further towards clinical proof-of-concept. Conclusion: The article's description of what investors are looking for in today's CGT market largely corresponds with the strategy Circio has communicated.
·40 min sitten10 mill at 16.10 must surely be summer holiday turnover. And a full 2 months since the last visible short. There will probably be more action from August onwards. No one else but possibly a few biotech insiders know anything about a bid. If and when... In the meantime, we can only hope.
·1 t sittenLooks like we have short-term technical resistance at 7.60kr📈 And short-term support at 7.20kr 📉 Just waiting for news…🍺 Will be exciting going forward..😃👍🏼
Not to rub salt in the wound, but I have noticed that BP over the years has developed cunning methods against such small fry as Cirico. They want to cooperate, and at the same time have access to various data. After a while, they themselves have developed a method that is preferably somewhat better. So I hope the company has obtained patents that are more watertight than the bulkheads on the Titanic were, so to speak.
·2 t sittenTraded for under 10 mill. I remember when It was traded for 10 mill in half an hour
It can happen before you know it. Work is constantly being done, and news can come at any time. We're not whispering about that anymore....- ·2 t sittenEverything that's happening around Circio's technology is starting to become massive…🔥
Yes, that's right, and let's look back a bit. Reminisce a bit about what has happened and what remains. I think the holiday reassures us and a juicy announcement will appear after Eric and co have brooded on the eggs during the holiday💥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
91 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·33 min sitten · MuokattuArticle with Erik Wiklund from today https://themedicinemaker.com/issues/2026/articles/july/surviving-cgts-funding-winter/Article: Investors are now only funding the strongest CGT companies. * Circio: Has raised approx. NOK 620 million (USD 65 mill.) in 2026, which shows that the company has managed to attract significant capital in a demanding market. Article: Long cash reserves ("runway") are a major competitive advantage. * Circio: States that the financing provides operations until the end of 2030, which reduces the risk of new share issues in the short term. Article: Platform technologies are valued higher than single products. * Circio: Focuses on circVec, a circular RNA platform that can be used in several types of gene and cell therapies, not just one drug. Article: Partnerships with Big Pharma are becoming increasingly important. * Circio: Has already announced a collaboration with a top-5 global pharmaceutical company, which aligns well with this trend. Article: Companies must show a clear path towards clinical trials. * Circio: Has stated that the capital will be used to take a leading gene therapy program to IND and further towards clinical proof-of-concept. Conclusion: The article's description of what investors are looking for in today's CGT market largely corresponds with the strategy Circio has communicated.
- ·40 min sitten10 mill at 16.10 must surely be summer holiday turnover. And a full 2 months since the last visible short. There will probably be more action from August onwards. No one else but possibly a few biotech insiders know anything about a bid. If and when... In the meantime, we can only hope.
- ·1 t sittenLooks like we have short-term technical resistance at 7.60kr📈 And short-term support at 7.20kr 📉 Just waiting for news…🍺 Will be exciting going forward..😃👍🏼Not to rub salt in the wound, but I have noticed that BP over the years has developed cunning methods against such small fry as Cirico. They want to cooperate, and at the same time have access to various data. After a while, they themselves have developed a method that is preferably somewhat better. So I hope the company has obtained patents that are more watertight than the bulkheads on the Titanic were, so to speak.
- ·2 t sittenTraded for under 10 mill. I remember when It was traded for 10 mill in half an hourIt can happen before you know it. Work is constantly being done, and news can come at any time. We're not whispering about that anymore....
- ·2 t sittenEverything that's happening around Circio's technology is starting to become massive…🔥Yes, that's right, and let's look back a bit. Reminisce a bit about what has happened and what remains. I think the holiday reassures us and a juicy announcement will appear after Eric and co have brooded on the eggs during the holiday💥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
91 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·33 min sitten · MuokattuArticle with Erik Wiklund from today https://themedicinemaker.com/issues/2026/articles/july/surviving-cgts-funding-winter/Article: Investors are now only funding the strongest CGT companies. * Circio: Has raised approx. NOK 620 million (USD 65 mill.) in 2026, which shows that the company has managed to attract significant capital in a demanding market. Article: Long cash reserves ("runway") are a major competitive advantage. * Circio: States that the financing provides operations until the end of 2030, which reduces the risk of new share issues in the short term. Article: Platform technologies are valued higher than single products. * Circio: Focuses on circVec, a circular RNA platform that can be used in several types of gene and cell therapies, not just one drug. Article: Partnerships with Big Pharma are becoming increasingly important. * Circio: Has already announced a collaboration with a top-5 global pharmaceutical company, which aligns well with this trend. Article: Companies must show a clear path towards clinical trials. * Circio: Has stated that the capital will be used to take a leading gene therapy program to IND and further towards clinical proof-of-concept. Conclusion: The article's description of what investors are looking for in today's CGT market largely corresponds with the strategy Circio has communicated.
- ·40 min sitten10 mill at 16.10 must surely be summer holiday turnover. And a full 2 months since the last visible short. There will probably be more action from August onwards. No one else but possibly a few biotech insiders know anything about a bid. If and when... In the meantime, we can only hope.
- ·1 t sittenLooks like we have short-term technical resistance at 7.60kr📈 And short-term support at 7.20kr 📉 Just waiting for news…🍺 Will be exciting going forward..😃👍🏼Not to rub salt in the wound, but I have noticed that BP over the years has developed cunning methods against such small fry as Cirico. They want to cooperate, and at the same time have access to various data. After a while, they themselves have developed a method that is preferably somewhat better. So I hope the company has obtained patents that are more watertight than the bulkheads on the Titanic were, so to speak.
- ·2 t sittenTraded for under 10 mill. I remember when It was traded for 10 mill in half an hourIt can happen before you know it. Work is constantly being done, and news can come at any time. We're not whispering about that anymore....
- ·2 t sittenEverything that's happening around Circio's technology is starting to become massive…🔥Yes, that's right, and let's look back a bit. Reminisce a bit about what has happened and what remains. I think the holiday reassures us and a juicy announcement will appear after Eric and co have brooded on the eggs during the holiday💥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt